This page contains press release content distributed by XPR Media. Members of the editorial and news staff of the USA TODAY Network were not involved in the creation of this content.

There is a Strong Business Case for Phase II Clinical Program for Treatment of MPox Infection Using NV-387, an Industry-Leading Broad-Spectrum Antiviral Drug Candidate

SHELTON, CT / ACCESS Newswire / July 1, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC ) (the “Company”), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, announces that it is forging ahead with advancing its lead candidate NV-387 into Phase II clinical drug development.

NanoViricides has chosen MPox as the first indication to advance NV-387 into Phase II clinical trials out of the four indications for which the Company has substantial efficacy data in animal studies, namely RSV, Influenza, COVID, and Orthopoxviruses (MPox/Smallpox).

The MPox program enables advancing its pipeline towards revenue in the fastest possible manner, the Company believes. The Company intends to advance NV-387 against respiratory infections soon after the Phase II clinical trial of NV-387 for the treatment of MPox infection gets under way.

NanoViricides has already added one Clinical trial Site to the MPox Phase II Program.

A Phase II Clinical Trial Protocol has been developed with the Principal Investigator at this site in the Democratic Republic of Congo (DRC), and this Protocol is undergoing final refinements.

A Clinical Trial Application is in development with many parts having been substantially completed.

NanoViricides has engaged a Clinical Research Organization (CRO) to organize and conduct this Phase II clinical trial for the treatment of MPox with NV-387, as previously stated, and this CRO has organized the Clinical Trial Site and is preparing the CTA with the Company’s inputs.

The manufacture of the drug substance NV-387 is substantially completed at the Company’s own facility. The manufacture of the drug product “NV-387 Oral Gummies” is in progress.

MPox as the first indication has several strategic benefits for the Company.

Firstly, because of the continuing epidemic in the African Region there is a strong need for the drug and also there is the ability to recruit patients and complete the clinical trial in a timely manner. Additionally, running clinical trials in the African Region is substantially less expensive than clinical trials in USA or Europe that the Company has planned for RSV, a commercially important indication with multi-billion dollar potential market.

Secondly, a proof of efficacy in humans of NV-387 against MPox would validate our use of lethal challenge animal models and would establish that our animal model data are predictive of human outcomes. This would have huge implications since our animal model data against every infection we have tested to date has demonstrated NV-387 to be substantially superior to existing drugs, viz. RSV, Influenza, COVID, and of course, MPox/Smallpox.

Thirdly, there is a strong financial case for choosing MPox as the indication. This business case has become even stronger with the failure of tecovirimat (Tpoxx) in clinical trial against MPox. Tecovirimat and brincidofovir (Tembexa) are the only two drugs approved by the US FDA for the treatment of Smallpox, a virus of bioterrorism concern. Both of these drugs were approved under the “FDA Animal Rule”, which eliminates the need for demonstration of efficacy in humans. The “FDA Animal Rule” is applicable for diseases such as Smallpox and others where clinical trials in human patients are not feasible or would be unethical.

These FDA approvals have led to the acquisition of these two drugs into the US Strategic National Stockpile (SNS) to the tune of billions of dollars. And now, there is a clear need for replacing these non-performing drugs with a drug that actually works against MPox and Smallpox (see further down below).

We believe NV-387 would become the choice for addition to the SNS if our proposed Phase II clinical trial against MPox demonstrates benefits of the NV-387 treatment.

The most recent acquisition contracts with BARDA for tecovirimat, which were for drug replenishments, have been valued at over $150million.

An initial stocking contract for NV-387 is likely to be substantially larger, as was the case with the initial acquisition of several drugs into the SNS.

Brincidofovir failed an early clinical trial against MPox due to liver toxicity. Tecovirimat failed a recent clinical trial against MPox since it demonstrated no superiority in efficacy over the standard of care.

Importantly, both of these drug candidates are small chemicals that the viruses can readily escape by mutations. Smallpox, if it ever becomes fielded as a bio-terrorism agent, is unlikely to be in the “original” form of the virus, and could be explicitly manipulated to breed resistance to such small chemical drugs by onerous entities.

Of note, MPox is in the same family as the Smallpox virus; MPox causes a much weaker form of disease than the Smallpox virus.

Thus there is a strong case for HHS to support NV-387 drug development for Bioterrorism Readiness.

The “NV-387 Oral Gummies” drug product is a soft solid formulation that is designed to stick in the oral cavity and dissolve naturally over time, with no solid object (pill or capsule) swallowing necessary. This is important for MPox because MPox causes lesions on mucosal surfaces that make swallowing painful and difficult. MPox is primarily known for the explicit characteristic painful rash on the external skin, but it is a significantly more severe disease than just a skin rash.

The MPox virus circulating in DRC and neighboring regions is of Clade 1a and Clade 1b subtypes, with the latter predominant. Clade 1b is more transmissible of the two, which is why it has resulted in a sustained epidemic. The MPox Clade 1a case fatality rate (CFR) is about 3%-11% whereas the CFR for Clade 1b is about 1%. The MPox Clade 2b is the virus causing continuing cases in the Western world, which causes a much less severe disease than Clade 1a/1b and has a very low CFR, according to CDC. Sporadic cases of Clade 1 in the Western world continue to occur. Four separate travel-related MPox Clade 1 cases reported in the USA that did not result in any further spread, since November 2024, according to the CDC ( https://www.cdc.gov/mpox/situation-summary/index.html ). Clearly, the threat of MPox Clade 1 causing a potential epidemic in the USA cannot be ignored, and readiness with a drug that works against the same is important to achieve.

ABOUT NANOVIRICIDES

NanoViricides, Inc. (the “Company”) ( www.nanoviricides.com ) is a publicly traded (NYSE-American, stock symbol NNVC) clinical stage company that is creating special purpose nanomaterials for antiviral therapy. The Company’s novel nanoviricide™ class of drug candidates and the nanoviricide™ technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. The Company has a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections. The MoU does not include cancer and similar diseases that may have viral origin but require different kinds of treatments.

The Company has obtained broad, exclusive, sub-licensable, field licenses to drugs developed in several licensed fields from TheraCour Pharma, Inc. The Company’s business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005.

Our lead drug candidate is NV-387, a broad-spectrum antiviral drug that we plan to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. Our other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. The Company cannot project an exact date for filing an IND for any of its drugs because of dependence on a number of external collaborators and consultants. The Company is currently focused on advancing NV-387 into Phase II human clinical trials.

The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides’ platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for RSV, Poxviruses, and/or Enteroviruses if the initial research is successful. As is customary, the Company must state the risk factor that the path to typical drug development of any pharmaceutical product is extremely lengthy and requires substantial capital. As with any drug development efforts by any company, there can be no assurance at this time that any of the Company’s pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development. Further, there can be no assurance at this time that successful results against coronavirus in our lab will lead to successful clinical trials or a successful pharmaceutical product.

This press release contains forward-looking statements that reflect the Company’s current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company’s control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company’s expectations include, but are not limited to, those factors that are disclosed under the heading “Risk Factors” and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.

The phrases “safety”, “effectiveness” and equivalent phrases as used in this press release refer to research findings including clinical trials as the customary research usage and do not indicate evaluation of safety or effectiveness by the US FDA.

FDA refers to US Food and Drug Administration. IND application refers to “Investigational New Drug” application. cGMP refers to current Good Manufacturing Practices. CMC refers to “Chemistry, Manufacture, and Controls”. CHMP refers to the Committee for Medicinal Products for Human Use, which is the European Medicines Agency’s (EMA) committee responsible for human medicines. API stands for “Active Pharmaceutical Ingredient”. WHO is the World Health Organization. R&D refers to Research and Development.

Contact:
NanoViricides, Inc.
info@nanoviricides.com

Public Relations Contact:
ir@nanoviricides.com

SOURCE: NanoViricides, Inc.

View the original press release on ACCESS Newswire

Information contained on this page is provided by an independent third-party content provider. XPRMedia and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact pressreleases@xpr.media

Processa Pharmaceuticals and BullFrog AI Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Processa Pharmaceuticals and BullFrog AI Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

ORLANDO, FLORIDA / ACCESS Newswire / July 18, 2025 / RedChip Companies will air interviews with Processa Pharmaceuticals, Inc. (Nasdaq:PCSA) and BullFrog AI, Inc. (Nasdaq:BFRG)…

July 18, 2025

Safe Pro Selected by U.S. Government Contractor to Provide Ballistic Protection Gear in Indo-Asia Pacific Region & Demonstrate AI-Powered Drone Technology for Landmine Detection

Safe Pro Selected by U.S. Government Contractor to Provide Ballistic Protection Gear in Indo-Asia Pacific Region & Demonstrate AI-Powered Drone Technology for Landmine Detection

Delivery of U.S.-Manufactured Ballistic Protection Products Expected in Q3; AI Demonstration Supports U.S. DoD Operational Objectives in the Pacific Rim AVENTURA, FLORIDA / ACCESS Newswire…

July 18, 2025

The IRS Is Watching Social Media – Clear Start Tax Warns Creators About the Risks of Monetized Content

The IRS Is Watching Social Media – Clear Start Tax Warns Creators About the Risks of Monetized Content

Clear Start Tax breaks down how income from platforms like TikTok, YouTube, and Instagram can trigger audits if not reported correctly. IRVINE, CA / ACCESS…

July 18, 2025

Telomir Demonstrates Telomir-1 Reverses Epigenetic Gene Silencing of STAT1, Restoring Tumor Suppressor in Human Prostate Cancer Cells, Outperforming Chemotherapy and Rapamycin

Telomir Demonstrates Telomir-1 Reverses Epigenetic Gene Silencing of STAT1, Restoring Tumor Suppressor in Human Prostate Cancer Cells, Outperforming Chemotherapy and Rapamycin

New data shows Telomir-1 fully reverses STAT1 gene silencing by DNA methylation – a key immune regulator suppressed in cancer – delivering stronger epigenetic effects…

July 18, 2025

Walkrite Foot Clinic Wins 2025 Consumer Choice Award for Podiatry and Foot Care in Toronto Central

Walkrite Foot Clinic Wins 2025 Consumer Choice Award for Podiatry and Foot Care in Toronto Central

TORONTO, ONTARIO / ACCESS Newswire / July 18, 2025 / Walkrite Foot Clinic, a trusted name in expert podiatric care for over two decades, has…

July 18, 2025

Northern Superior Completes the Acquisition of Strategic Properties in The Chibougamau Gold Camp

Northern Superior Completes the Acquisition of Strategic Properties in The Chibougamau Gold Camp

TORONTO, ON / ACCESS Newswire / July 18, 2025 / Northern Superior Resources Inc. (“ Northern Superior ” or the “ Company “) (TSX-V:SUP)(OTCQX:NSUPF)(GR:D9M1) is…

July 18, 2025

Arrive AI and AllMart/ACT Antigua to Expand Secure Deliveries in Antigua

Arrive AI and AllMart/ACT Antigua to Expand Secure Deliveries in Antigua

INDIANAPOLIS, IN AND ST. JOHN’S ANTIGUA / ACCESS Newswire / July 18, 2025 / Arrive AI (NASDAQ:ARAI) – a pioneering autonomous delivery network anchored by…

July 18, 2025

GTA’s Consumer Direct Windows & Doors Wins 2025 Consumer Choice Award for Windows and Doors

GTA’s Consumer Direct Windows & Doors Wins 2025 Consumer Choice Award for Windows and Doors

TORONTO, ONTARIO / ACCESS Newswire / July 18, 2025 / Consumer Direct Windows & Doors, a trusted local leader in premium windows and doors, has…

July 18, 2025

Durham Region’s Counter Reactions Celebrated with 2025 Consumer Choice Award for Countertops

Durham Region’s Counter Reactions Celebrated with 2025 Consumer Choice Award for Countertops

UXBRIDGE, ON / ACCESS Newswire / July 18, 2025 / Counter Reactions, a trusted local stone fabricator known for its craftsmanship and personal touch, has…

July 18, 2025

Organto Completes Fee Payment to Jaluca Limited

Organto Completes Fee Payment to Jaluca Limited

VANCOUVER, BC AND BREDA, THE NETHERLANDS / ACCESS Newswire / July 17, 2025 / Organto Foods Inc. (TSXV:OGO)(OTC PINK:OGOFF) (“Organto” or the “Company“) announces that…

July 17, 2025

Advanced Networks Transforms IT Support in LA to Improve Network Security and Safeguard Businesses

Advanced Networks Transforms IT Support in LA to Improve Network Security and Safeguard Businesses

Advanced Networks, a top provider of Managed IT Services and IT support in Southern California, is tackling the pressing need for better network security among…

July 17, 2025

LQR House Signals Potential Strategic Shift Toward Digital Assets with Support from a Significant Crypto Investor

LQR House Signals Potential Strategic Shift Toward Digital Assets with Support from a Significant Crypto Investor

Company Sets Sights on Becoming a Crypto-Integrated Brand Platform, Leveraging Strong Ecommerce Foundation and Industry Collaboration MIAMI BEACH, FLORIDA / ACCESS Newswire / July 17,…

July 17, 2025

Rent Like A Champion Acquires CollegeWeekends

Rent Like A Champion Acquires CollegeWeekends

Rent Like A Champion adds market capacity and new customers to expand its national footprint in college town markets and youth sports destinations Jul. 17,…

July 17, 2025

The Build Show Welcomes Mike Conneely

The Build Show Welcomes Mike Conneely

Chicago area builder joins the Build Expert team AUSTIN, TX / ACCESS Newswire / July 17, 2025 / As the leading provider of residential construction…

July 17, 2025

Larry Weltman Publishes New Blog on the Fulfilment of Helping Real Estate Professionals Succeed

Larry Weltman Publishes New Blog on the Fulfilment of Helping Real Estate Professionals Succeed

Larry Weltman reflects on the value of working behind the scenes – showing how consistent, quiet support can empower others to thrive in business and…

July 17, 2025

How to Get Cited in AI Overviews: A Tactical Guide

How to Get Cited in AI Overviews: A Tactical Guide

The HOTH Launches Tactical Guide on Getting Cited in AI Overviews St. Petersburg, FL – July 15, 2025 – The HOTH, a leader in search engine…

July 17, 2025

CelluHeal™ Launches Full Line of Advanced Wound Dressings for Online Purchase in the USA, Canada, and Beyond

CelluHeal™ Launches Full Line of Advanced Wound Dressings for Online Purchase in the USA, Canada, and Beyond

Jul. 17, 2025 / PRZen / WASHINGTON, Md. & VANCOUVER, British Columbia — CelluHeal™, a trusted provider of advanced wound care supplies, is pleased to…

July 17, 2025

FOB Summit Champions Local Manufacturing for a Resilient US Battery Supply Chain

FOB Summit Champions Local Manufacturing for a Resilient US Battery Supply Chain

NEW YORK CITY, NY / ACCESS Newswire / July 17, 2025 / As energy storage demand surges in the US amid battery tariffs and rising…

July 17, 2025

Latest GA Autonomous Jet Demo Features Live Air-to-Air Engagement Capability

Latest GA Autonomous Jet Demo Features Live Air-to-Air Engagement Capability

Autonomous Tasking With TacACE and Optix.C2 Showcase Maturity and Operational Readiness SAN DIEGO, CALIFORNIA / ACCESS Newswire / July 17, 2025 / General Atomics Aeronautical…

July 17, 2025

Belgian Aircrew Completes MQ-9B Training

Belgian Aircrew Completes MQ-9B Training

GA-ASI’s MQ-9B SkyGuardian® Training Was Conducted at Multiple Sites, Including Flight Test & Training Center and Desert Horizon SAN DIEGO, CALIFORNIA / ACCESS Newswire /…

July 17, 2025

AI startup Congero offers instant websites with 24/7 updates – aiming to replace web agencies

AI startup Congero offers instant websites with 24/7 updates – aiming to replace web agencies

Jul. 17, 2025 / PRZen / SAN FRANCISCO — A new AI-powered web service, Congero, is now helping time-poor small business owners launch and maintain…

July 17, 2025

Liberty Helps Australians Access Flexible Home Loan Options

Liberty Helps Australians Access Flexible Home Loan Options

With home loan demand rising year-on-year, Liberty continues to support a range of Australians to enter the property market. MELBOURNE, AUSTRALIA / ACCESS Newswire /…

July 17, 2025

Liberty Supports Regional Relocation With Flexible Personal Loans

Liberty Supports Regional Relocation With Flexible Personal Loans

As more Australians seek a lifestyle change, leading non-bank lender Liberty is helping to make regional relocation more accessible through tailored personal loan solutions. MELBOURNE,…

July 17, 2025

A New Transatlantic Partnership for European CCA

A New Transatlantic Partnership for European CCA

General Atomics announces plans for rapid international uncrewed fighter development FAIRFORD, UK / ACCESS Newswire / July 17, 2025 / General Atomics is taking a…

July 17, 2025

DeepStreet.io Launches Market Intelligence Platform to Deliver Credible, Performance-Linked Investment Insight

DeepStreet.io Launches Market Intelligence Platform to Deliver Credible, Performance-Linked Investment Insight

New Research Platform Gives Sophisticated Investors Access to Real-Time Insight from Verified Professionals with Full Visibility into Performance RED BANK, NJ / ACCESS Newswire /…

July 17, 2025

1933 Industries Reminds Shareholders to Vote at the Upcoming Annual General Meeting

1933 Industries Reminds Shareholders to Vote at the Upcoming Annual General Meeting

VANCOUVER, BC / ACCESS Newswire / July 17, 2025 / 1933 Industries Inc. (the “Company” or “1933 Industries”) (CSE:TGIF)(OTC PINK:TGIFF), a Nevada-focused cannabis cultivator and…

July 17, 2025

GPOPlus+ to Present Growth Strategy at Liberty Ventures Investor Summit in Chicago

GPOPlus+ to Present Growth Strategy at Liberty Ventures Investor Summit in Chicago

CEO Brett H. Pojunis to Highlight Expansion, Profitability Gains, and Vision to Scale to 20,000+ National Retail Partners LAS VEGAS, NEVADA / ACCESS Newswire /…

July 17, 2025

CEO Update: Brenmiller’s Strategic Alignment with the EU’s €1B Innovation Fund Gains Momentum

CEO Update: Brenmiller’s Strategic Alignment with the EU’s €1B Innovation Fund Gains Momentum

As the EU launches its €1 billion Innovation Fund to decarbonize industrial heat, Brenmiller enters as a proven, strategically aligned participant-backed by operational collaborations across…

July 17, 2025

AI Phishing, Deepfakes & Other Cybersecurity Threats Facing NY SMBs in 2025

AI Phishing, Deepfakes & Other Cybersecurity Threats Facing NY SMBs in 2025

New Windsor, New York / Syndication Cloud / July 17, 2025 / Fisch Solutions Key Summary Rising AI threats: Cybercriminals increasingly use artificial intelligence to…

July 17, 2025

Kingbird Ventures Files Legal Action Against LQR House Inc. Seeking Court-Appointed Receiver

Kingbird Ventures Files Legal Action Against LQR House Inc. Seeking Court-Appointed Receiver

MIAMI BEACH, FLORIDA / ACCESS Newswire / July 17, 2025 / Kingbird Ventures, LLC, an affiliate of Diveroli Investment Group (DIG), has filed a complaint…

July 17, 2025

4-Star Electric Wins 2025 Consumer Choice Award for Electrical Contractors in Southern Alberta

4-Star Electric Wins 2025 Consumer Choice Award for Electrical Contractors in Southern Alberta

Calgary’s trusted family-owned electrical company recognized for outstanding service, safety, and customer satisfaction. CALGARY, ALBERTA / ACCESS Newswire / July 17, 2025 / 4-Star Electric…

July 17, 2025

LQR House Announces Intent to Invest in Bitmain Mining Equipment for Potential Deployment at Polaris Capital’s U.S. Bitcoin Mining Farms

LQR House Announces Intent to Invest in Bitmain Mining Equipment for Potential Deployment at Polaris Capital’s U.S. Bitcoin Mining Farms

Company Intends to Advance Bitcoin Treasury Strategy with Plans to Enter Mining Infrastructure for Long-Term Yield Generation MIAMI BEACH, FLORIDA / ACCESS Newswire / July…

July 17, 2025

The Spider Guys Recognized for Superior Service with 2025 Consumer Choice Award in Pest Control for Windsor

The Spider Guys Recognized for Superior Service with 2025 Consumer Choice Award in Pest Control for Windsor

WINDSOR, ON / ACCESS Newswire / July 17, 2025 / The region’s trusted defenders against unwanted intruders have officially earned top honours. The Spider Guys…

July 17, 2025

Principled Craftsmanship, Trusted Results: Principal Roofing & Exterior Contractors Wins 2025 Consumer Choice Award in York Region

Principled Craftsmanship, Trusted Results: Principal Roofing & Exterior Contractors Wins 2025 Consumer Choice Award in York Region

AURORA, ON / ACCESS Newswire / July 17, 2025 / Principal Roofing & Exterior Contractors, a standout name in the roofing and exterior contracting space,…

July 17, 2025

Cerrado Gold Announces Q2 2025 Production Results at Its Minera Don Nicolas Mine in Argentina

Cerrado Gold Announces Q2 2025 Production Results at Its Minera Don Nicolas Mine in Argentina

Gold Equivalent Ounce (“GEO”) Production of 11,437 GEO for the 2nd Quarter 2025 Underground Development has commenced and production set to ramp up in H2/2025…

July 17, 2025

Completion of Additional Regional Soil Sampling Programs

Completion of Additional Regional Soil Sampling Programs

Testing regional exploration targets in ‘Stage 1′ development area HIGHLIGHTS Soil sampling recently completed over ~1.9km2 surrounding Tolmer high-grade silver discovery[1] Additional ~23km2 program completed…

July 16, 2025

GameSquare Holdings, Inc. Announces Proposed Public Offering of Common Stock

GameSquare Holdings, Inc. Announces Proposed Public Offering of Common Stock

FRISCO, TEXAS / ACCESS Newswire / July 16, 2025 / GameSquare Holdings, Inc. (NASDAQ:GAME) (the “Company” or “GameSquare”) a next-generation media company with roots in…

July 16, 2025

Precision Reloading Expands with Nosler, Bullets, Brass, and Ammunition to Elevate Shooting Experience

Precision Reloading Expands with Nosler, Bullets, Brass, and Ammunition to Elevate Shooting Experience

Precision Reloading is excited to announce an important update to its range of outdoor products. Responding to the needs of its customers, the company is…

July 16, 2025

Amber Ridge Condos for Sale in Summerlin: Discover with Las Vegas Homes By Leslie – RE/ MAX United Realtor

Amber Ridge Condos for Sale in Summerlin: Discover with Las Vegas Homes By Leslie – RE/ MAX United Realtor

Las Vegas Homes By Leslie – RE/MAX United Realtor, a well-respected real estate agency led by experienced realtor Leslie Hoke, is excited to announce the…

July 16, 2025

Dr. Todd H. Lanman to Present at International Total Disc Arthroplasty Masterclass in Amsterdam

Dr. Todd H. Lanman to Present at International Total Disc Arthroplasty Masterclass in Amsterdam

BEVERLY HILLS, CA / ACCESS Newswire / July 18, 2025 / World-renowned spinal neurosurgeon and motion preservation expert Dr. Todd H. Lanman will join an…

July 16, 2025